Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib.

Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib.

Portal hypertension, the most important complication with cirrhosis of the liver, is a serious disease. Sorafenib, a tyrosine kinase inhibitor is validated in advanced hepatocellular carcinoma. Because angiogenesis is a pathological hallmark of portal hypertension, the goal of our study was to deter...

Full description

Bibliographic Details
Main Authors: Romain Coriat, Hervé Gouya, Olivier Mir, Stanislas Ropert, Olivier Vignaux, Stanislas Chaussade, Philippe Sogni, Stanislas Pol, Benoit Blanchet, Paul Legmann, François Goldwasser
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-02-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21340026/?tool=EBI

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21340026/?tool=EBI

Similar Items